Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells
from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by
blocking the enzymes necessary for their growth. Combining docetaxel with gefitinib may kill
more tumor cells. It is not yet known whether docetaxel is more effective with or without
gefitinib in treating head and neck cancer. This randomized phase III trial is studying
docetaxel and gefitinib to see how well they work compared to docetaxel alone in treating
patients with metastatic or locally recurrent head and neck cancer.